3-(2,6-dimethyl-piperidin-1-yl)-propan-1-ol | 79156-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(2,6-dimethyl-piperidin-1-yl)-propan-1-ol
• 英文别名: 2,6-dimethyl-1-(3-hydroxypropyl)piperidine；3-(2,6-Dimethylpiperidin-1-YL)propan-1-OL
• CAS: 79156-90-4
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: CRDBTWHALLRFOX-UHFFFAOYSA-N

物化性质

• 沸点：
  149 °C(Press: 30 Torr)
• 密度：
  0.905±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-(2,6-dimethyl-piperidin-1-yl)-propan-1-ol 在 mercury(II) diacetate 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 18.5h， 生成 6,9a-dimethyl-hexahydro-pyrido[2,1-b][1,3]oxazine
  参考文献：
  名称：

  Unsaturated Amines. XVI. An Oxidative Cyclization Route to Oxazolidines and Tetrahydro-1,3-oxazines^1,2

  摘要：

  DOI：

  10.1021/ja01504a032
• 作为产物：
  描述：

  2,6-二甲基哌啶 、 3-溴-1-丙醇 以 四氢呋喃 为溶剂， 生成 1-(3-chloro-propyl)-2,6-cis-dimethyl-piperidine 、 3-(2,6-dimethyl-piperidin-1-yl)-propan-1-ol
  参考文献：
  名称：

  Treating cardiac arrhythmias

  摘要：

  含有9-氨基烷基取代基的芴衍生物是有用的抗心律失常药物。本发明提供了含有该化合物的药物制剂，以及治疗方法。

  公开号：

  US04277495A1

文献信息

• 4-Substituted quinolines as antitumor agents
  申请人：Boyle Thomas Francis

  公开号：US20050101630A1

  公开（公告）日：2005-05-12

  The invention concerns compounds of formula (1), wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmnaceutical compositions containing them and their use in the manufacture of a medicament for use as an anliiproliferative agent in the treatment of solid tumour disease.

  本发明涉及公式（1）的化合物，其中R1、R2、R3、R4、R5、R6、R8、R9、R10、m、n、p、X、Y和Z中的每一个都有在说明书中定义的任何含义，以及它们的制备方法、含有它们的药物组合物，以及它们在制备用于治疗固体肿瘤疾病的药物中作为抗增殖剂的用途。
• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。
• Indazole compounds and methods of use thereof as protein kinase inhibitors
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：EP2065383A1

  公开（公告）日：2009-06-03

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶液剂和水合物。吲唑化合物可用于治疗或预防对激酶的抑制、调节或调控有反应的多种疾病和失调，如炎症性疾病、异常血管生成及其相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫性疾病、黄斑变性、与疾病相关的消瘦、与石棉相关的疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还公开了治疗或预防此类疾病和失调的方法，以及包含一种或多种吲唑化合物的药物组合物。本发明部分基于对一类新型 5-三唑取代的吲唑分子的发现，该类分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和肠外活性分子，这些分子可以较低的剂量或血清浓度用于治疗与蛋白激酶信号转导有关的疾病或紊乱。
• 9-Aminoalkylfluorenes, process therefor and antiarrhythmic formulations thereof
  申请人：ELI LILLY AND COMPANY

  公开号：EP0018076B1

  公开（公告）日：1983-09-21